Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.

Cancer letters - 1 Sept 2018

Zhao Xiao, Liu Liang, Lang Jiayan, Cheng Keman, Wang Yongwei, Li Xueyan, Shi Jian, Wang Yanli, Nie Guangjun

Abstract excerpt

Mutant KRAS is a known driver oncogene in pancreatic cancer. However, this protein remains an "undruggable" therapeutic target. Inhibiting mutated KRAS expression at the mRNA level is a potentially effective strategy. Recently, a novel CRISPR-Cas effector, Cas13a has been reported to specifically knock down mRNA expression under the guidance of a single CRISPR-RNA in mammalian cells. Here we demonstrate that the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to CRISPR-Cas Systems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Neoplasm Transplantation

Share to Oncogenes

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA Interference

Source

Identifiers

PMID: 29870774
DOI: 10.1016/j.canlet.2018.05.042

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.PMID 29870774Read ↗

CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines.Semantic proximity Read ↗

Efficacy of CRISPR-Cas9 Gene Editing for Targeting KRAS Mutations in Pancreatic Cancer: A systematic reviewSemantic proximity Read ↗

CRISPR/Cas technologies in pancreatic cancer research and therapeutics: recent advances and future outlookSemantic proximity Read ↗

CRISPR and KRAS: a match yet to be made.Semantic proximity Read ↗

Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.Semantic proximity Read ↗

Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression.Semantic proximity Read ↗

Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells.Semantic proximity Read ↗

Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression.Semantic proximity Read ↗

CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancersSemantic proximity Read ↗

Selective targeting of an oncogenic <i>KRAS</i> mutant allele by CRISPR/Cas9 induces efficient tumor regressionSemantic proximity Read ↗

CRISPR/Cas9 and cancer targets: future possibilities and present challenges.Semantic proximity Read ↗

Survival of pancreatic cancer cells lacking KRAS functionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.